RAFAEL HOLDINGS, INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
RAFAEL HOLDINGS, INC. (RFL) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$8.69 million for the 12-month period ending 2023-07-31, per its 10-K filed 2023-10-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2023-10-30
- RAFAEL HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2023-07-31 was $1.26M.
- RAFAEL HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2023-04-30 was -$1.49M.
- RAFAEL HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2023-01-31 was -$3.09M.
- RAFAEL HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2022-10-31 was -$5.11M.
- RAFAEL HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$8.69M.
- RAFAEL HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was -$140.55M.
- RAFAEL HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2021 was -$23.06M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2023-07-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-30 | -$234.00K derived: sum of 2 quarters · filed 2023-10-30 | -$3.33M derived: sum of 3 quarters · filed 2023-10-30 | -$8.69M 10-K · filed 2023-10-30 |
| 2023-04-30 | -$1.49M 10-Q · filed 2023-06-13 | -$4.58M derived: sum of 2 quarters · filed 2023-06-13 | -$9.95M 10-Q · filed 2023-06-13 | -$14.33M derived: sum of 4 quarters · filed 2023-10-30 |
| 2023-01-31 | -$3.09M 10-Q · filed 2023-03-14 | -$8.20M 10-Q · filed 2023-03-14 | -$12.84M derived: sum of 3 quarters · filed 2023-10-30 | -$17.82M derived: sum of 4 quarters · filed 2023-10-30 |
| 2022-10-31 | -$5.11M 10-Q · filed 2022-12-13 | -$9.75M derived: sum of 2 quarters · filed 2023-10-30 | -$14.73M derived: sum of 3 quarters · filed 2023-10-30 | -$16.54M derived: sum of 4 quarters · filed 2023-10-30 |
| 2022-07-31 | -$4.64M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-30 | -$9.62M derived: sum of 2 quarters · filed 2023-10-30 | -$11.44M derived: sum of 3 quarters · filed 2023-10-30 | -$140.55M 10-K · filed 2023-10-30 |
| 2022-04-30 | -$4.98M 10-Q · filed 2023-06-13 | -$6.80M derived: sum of 2 quarters · filed 2023-06-13 | -$135.91M 10-Q · filed 2023-06-13 | |
| 2022-01-31 | -$1.81M 10-Q · filed 2023-03-14 | -$113.29M 10-Q · filed 2023-03-14 | ||
| 2021-10-31 | -$111.48M 10-Q · filed 2022-12-13 | |||
| 2021-07-31 | -$23.06M 10-K · filed 2022-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |